Telepatia Secures $33M Series A

Venture capital firm a16z is leading a $33 million Series A investment in Telepatia, an AI-powered healthcare platform targeting Latin America’s critical clinician shortage. The funding round marks a significant bet on AI's potential to reshape healthcare delivery in underserved regions. According to a16z Blog, the investment aims to tackle the region's deficit of 43% fewer physicians and 65% fewer nurses per capita compared to OECD countries.

Founded by Nicolás Abad, whose father, a Colombian doctor nicknamed "Telepatia," died from a preventable medical error, the company's mission is deeply personal. Abad aims to build the AI product his father, a physician, would have embraced.

Telepatia's AI-native platform integrates documentation, clinical decision support, and a suite of AI healthcare employees, including AI doctors and nurses. These tools are designed to work within existing hospital systems, trained on clinical guidelines and local protocols. The company highlights the potential for emerging markets to leapfrog existing infrastructure challenges.

Since its launch in July 2025, Telepatia has been deployed across 25 hospital systems in Brazil, Colombia, and Mexico, reaching 14 million patients. Physicians using the platform have reportedly recovered an average of 1.7 hours daily, time now redirected towards patient care.

The platform has also reported preventing 60,000 medical errors in real-time. José Henrique Dias Salvador, CEO of Mater Dei in Brazil, noted the exceptional adoption rate, stating, "Our physicians use Telepatia eight hours a day. We’ve never seen adoption like that." This high engagement is crucial in a region where the top 100 health institutions employ half of all physicians.

The round includes participation from notable figures such as Palantir CTO Shyam Sankar, Rappi founder Simón Borrero, and Nubank founder David Vélez, underscoring confidence in Telepatia's disruptive potential in Latin America. Abad's long-term vision is to achieve a Nobel Prize in Medicine, inspired by AI's growing influence on scientific breakthroughs.